Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After rising sharply in recent days, Ocugen shares are again falling on news that the company is issuing $50 million of common stock. The post OCGN Stock Alert: The $50 Million Reason Ocugen Is Tanking Today appeared first on InvestorPlace.

OCGN Stock Alert: The $50 Million Reason Ocugen Is Tanking Today

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the pricing of its underwritten public offering of approximately 15,973,420 million shares of its common stock for gross proceeds of approximately $53.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about February 25, 2022, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to approximately 2,396,013 million additional shares of its common stock.

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

Ocugen's path to entry in the North American market is highly uncertain, making OCGN stock a remarkably risky bet at this point. The post Ocugen Is Too Uncertain as Time Runs Out for Covaxin's Approval appeared first on InvestorPlace.

Ocugen Is Too Uncertain as Time Runs Out for Covaxin's Approval

Krispy Kreme

A host of worries pulled the broader market lower after the long holiday weekend.

Even a Falling Nasdaq Couldn't Stop These 2 Stocks Tuesday

The FDA lifted a clinical hold that had been preventing Ocugen from starting a U.S.-based phase 3 clinical study of its COVID-19 vaccine.

Why Ocugen Stock Is Skyrocketing Today

Shares of OCGN stock are flying higher after the FDA lifted its clinical hold on Covaxin, the company's coronavirus drug candidate. The post OCGN Stock Alert: Why Is Ocugen Heating Up Today?

OCGN Stock Alert: Why Is Ocugen Heating Up Today?

Imperial Petroleum

Phunware Inc

What you need to know about trading penny stocks on February 22nd The post Trading Penny Stocks? Top Stock Market News for February 22nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 22nd, 2022

Ocugen Inc (NASDAQ: OCGN) shares are trading higher by 23.8% at $4.28 Tuesday morning after the company announced the FDA lifted its clinical hold on the company's COVID-19 vaccine study in the US. "We are pleased to be able to move our clinical program for Covaxin forward, which we hope.

Why Ocugen Shares Are Rising

The stock price of Ocugen, Inc. (NASDAQ: OCGN) increased by over 17% pre-market today. This is why it happened.

Ocugen (OCGN) Stock: Why Its Surging Today

The FDA has lifted its clinical hold on Ocugen Inc's (NASDAQ: OCGN) investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. "We are pleased to be able to move our clinical program for Covaxin forward, which.

FDA Lifts Clinical Hold On Ocugen's COVID-19 Vaccine Study In US

Until the hype surrounding its Covid-19 vaccine candidate is no longer priced into shares, it's best to avoid OCGN stock. The post Despite an 80% Drop, Ocugen Stock Is Still Too Pricey appeared first on InvestorPlace.

Despite an 80% Drop, Ocugen Stock Is Still Too Pricey

An interview with Dr. Anthony Fauci about the Covaxin vaccine makes you wonder why investors have any interest in Ocugen and OCGN stock.  The post Ocugen Stock Finally Sunk to Penny Status, But That Doesn't Make It a Buy appeared first on InvestorPlace.

Ocugen Stock Finally Sunk to Penny Status, But That Doesn't Make It a Buy

OCGN stock is definitely out of favor on Wall Street, but fresh poll data and an imminent R&D hub acquisition should spur some optimism. The post Americans' Appetite for Vaccine Options Bodes Well for Ocugen appeared first on InvestorPlace.

Americans' Appetite for Vaccine Options Bodes Well for Ocugen

Shares of Ocugen Inc. ( OCGN , Financial) leaped by 28.03% to $4.43 after trading closed on Friday, CNBC reported. The sharp rise came after the U.S. Food and Drug Administration lifted its clinical hold on the Malvern, Pennsylvania-based company's investigational new drug application to evaluate a candidate for a Covid-19 vaccine.

Ocugen Pops 28.03% on FDA News

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, February 25, 2022.

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

If you're investing in OCGN stock, you have to wonder: how much upside can FDA approval really give this beleaguered name? The post Ocugen Stock Is a Fairy Tale in Need of a Happy Ending appeared first on InvestorPlace.

Ocugen Stock Is a Fairy Tale in Need of a Happy Ending

Dynavax Technologies

Novavax

A broad stock market rebound and an encouraging survey appear to be boosting these vaccine stocks.

Why Novavax, Dynavax, and Ocugen Are All Rising Today

MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- More than one year after the first COVID-19 vaccination was administered in the United States and more than 545 million doses later, new data from a survey conducted online by The Harris Poll February 3-7, 2022, among over 2,000 U.S. adults, on behalf of Ocugen, Inc., show a majority of Americans want more COVID-19 vaccines options to choose from. Nearly three quarters of Americans (73%) would like to see additional vaccine options available that are developed from a more traditional method, such as those used for diphtheria, mumps, chickenpox, or polio, which have been used for decades in children and adults.

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

Transocean

Southwestern Energy

Are these penny stocks on your watchlist right now? The post Good Penny Stocks to Invest In?

Good Penny Stocks to Invest In? 3 to Watch in 2022

Ocugen was one of the most explosive stocks on the market, all thanks to its coronavirus vaccine, Covaxin. But don't rush to buy just yet.

Two Reasons to Skip Ocugen Stock Despite Some Good News

Holding out hope for a Covid vaccine approval that might never come, OCGN stock is too risky while the company has no revenue. The post With No Vaccine Approval, Ocugen Is the Definition of Dead Money appeared first on InvestorPlace.

With No Vaccine Approval, Ocugen Is the Definition of Dead Money

Its value has dropped substantially in recent months. Could the biotech's fortunes change this year?

2 Green Flags for Ocugen's Future

Wish

Their shares have incurred heavy losses in recent months, and the worst may still be ahead.

2 Cash-Burning Growth Stocks to Stay Far Away From

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.

News for Ocugen, Inc. Stock (OCGN)